T. Rowe Price Associates’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-419,848
| Closed | -$28.5M | – | 2591 |
|
|
2019
Q3 | $28.5M | Sell |
419,848
-8,685
| -2% | -$596K | ﹤0.01% | 1044 |
|
|
2019
Q2 | $24.9M | Buy |
428,533
+5,279
| +1% | +$313K | ﹤0.01% | 1118 |
|
|
2019
Q1 | $29.6M | Buy |
423,254
+550
| +0.1% | +$40.8K | ﹤0.01% | 1050 |
|
|
2018
Q4 | $27.2M | Buy |
422,704
+35,726
| +9% | +$2.5M | ﹤0.01% | 1046 |
|
|
2018
Q3 | $27.2M | Buy |
386,978
+381,772
| +7,333% | +$22.3M | ﹤0.01% | 1118 |
|
|
2018
Q2 | $262K | Buy |
+5,206
| New | +$207K | ﹤0.01% | 2386 |
|
|
2017
Q4 | – | Sell |
-9,178
| Closed | -$295K | – | 2640 |
|
|
2017
Q3 | $295K | Buy |
9,178
+2,015
| +28% | +$63.6K | ﹤0.01% | 2291 |
|
|
2017
Q2 | $233K | Buy |
7,163
+3
| +0% | +$95 | ﹤0.01% | 2323 |
|
|
2017
Q1 | $225K | Hold |
7,160
| – | – | ﹤0.01% | 2359 |
|
|
2016
Q4 | $210K | Buy |
7,160
+230
| +3% | +$7.01K | ﹤0.01% | 2371 |
|
|
2016
Q3 | $200K | Sell |
6,930
-2,320
| -25% | -$64.6K | ﹤0.01% | 2355 |
|
|
2016
Q2 | $240K | Buy |
9,250
+100
| +1% | +$2.66K | ﹤0.01% | 2256 |
|
|
2016
Q1 | $227K | Buy |
9,150
+200
| +2% | +$5.49K | ﹤0.01% | 2262 |
|
|
2015
Q4 | $315K | Buy |
+8,950
| New | +$240K | ﹤0.01% | 2136 |
|
T. Rowe Price Associates's GHDX Position: Q4 2019 in Review
T. Rowe Price Associates sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 419,848 shares — an estimated $28.5M sold.
T. Rowe Price Associates first reported a position in GHDX in Q4 2015 and held it in 14 quarters. The position peaked at $29.6M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- T. Rowe Price Associates reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- T. Rowe Price Associates sold 419,848 Genomic Health, Inc. shares in Q4 2019, an estimated $28.5M.
- T. Rowe Price Associates first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 14 quarters.
- T. Rowe Price Associates's Genomic Health, Inc. position peaked at $29.6M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on T. Rowe Price Associates's 13F filing for Q4 2019, filed 14 Feb 2020.